3 Under-the-Radar Biotechs Under $5 That Could Soar 200%

Group 1: Biotechnology Investment Overview - Investing in biotechnology stocks is often seen as speculative due to many companies being in clinical or pre-clinical stages, typically not yet profitable and often pre-revenue [1] - Small-cap biotech stocks, particularly those trading under $5, may present opportunities for long-term returns for patient investors [2] Group 2: Hoth Therapeutics - Hoth Therapeutics (NASDAQ: HOTH) is currently priced at $1.46, down 35% from its 12-month high of $3.80, but has seen a 98% increase in 2025 [2][5] - The company has multiple pre-clinical assets, including an obesity drug candidate, and focuses on high-demand markets such as oncology and weight-loss treatments [3][5] - Hoth's pre-clinical oncology candidate, HT-KIT, has shown over 80% knockdown of KIT expression in laboratory settings, targeting aggressive cancers [4] - Analysts project a price target of $4 for Hoth, indicating a potential upside of 150% from current levels [5] Group 3: Silo Pharma - Silo Pharma (NASDAQ: SILO) is currently priced at $0.65, down 29% in 2025 but has gained over 7% in the last three months due to a joint venture with Hoth Therapeutics [7] - The partnership aims to develop Hoth's HT-VA obesity drug candidate, tapping into a market projected to exceed $100 billion globally [7] - Silo Pharma is also focused on developing novel formulations of traditional and psychedelic therapeutics, with four candidates in pre-clinical stages [8] - The company has launched a cryptocurrency treasury strategy, targeting investments in Bitcoin, Ethereum, and Solana [9] Group 4: Anixa Biosciences - Anixa Biosciences (NASDAQ: ANIX) is priced at $2.98 and is further along in its development, with two of its five drugs in Phase 1 clinical trials [10][11] - The company is developing its candidates through partnerships with notable institutions like the Moffitt Cancer Center and the Cleveland Clinic [12] - Analysts have set a consensus price target of $10 for Anixa, suggesting a potential upside of 197% [12]